Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Retained Earnings: 2009-2025

Historic Retained Earnings for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to -$1.5 billion.

  • Northwest Biotherapeutics' Retained Earnings fell 6.34% to -$1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year decrease of 6.34%. This contributed to the annual value of -$1.4 billion for FY2024, which is 6.16% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Retained Earnings stood at -$1.5 billion for Q3 2025, which was down 1.81% from -$1.5 billion recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Retained Earnings high stood at -$1.2 billion for Q4 2021, and its period low was -$1.5 billion during Q3 2025.
  • Moreover, its 3-year median value for Retained Earnings was -$1.4 billion (2024), whereas its average is -$1.4 billion.
  • Within the past 5 years, the most significant YoY rise in Northwest Biotherapeutics' Retained Earnings was 13.06% (2021), while the steepest drop was 64.28% (2021).
  • Northwest Biotherapeutics' Retained Earnings (Quarterly) stood at -$1.2 billion in 2021, then declined by 8.81% to -$1.3 billion in 2022, then dropped by 4.83% to -$1.4 billion in 2023, then decreased by 6.16% to -$1.4 billion in 2024, then dropped by 6.34% to -$1.5 billion in 2025.
  • Its Retained Earnings stands at -$1.5 billion for Q3 2025, versus -$1.5 billion for Q2 2025 and -$1.5 billion for Q1 2025.